Josh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC’s Halftime Report this week about large-cap ...

Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label risks keep it Hold—read now.

Investors will have to weigh the bull and bear cases to decide what to do with the stock. Past results are no guarantee of future returns. All stock market investors are familiar with this principle.

Last fall, first-year MBA students at Harvard Business School arrived at their classroom under an unusual circumstance: they had purposely not read a case prior to class. Professor Tony Mayo dimmed ...

Cognizant (Nasdaq: CTSH) released new research showing that companies pursuing AI adoption overwhelmingly prefer IT services firms - such as 'AI Builder' firms, a new services model defined by ...

Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating ...

Analysts believe this drugmaker is severely undervalued: Viking Therapeutics' average price target of $92.72 (according to ...

Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...

Private labels are usually invisible and price-led. But Swiggy Instamart wants them to be visible and aspirational. By ...

WIPO releases a study showing a slight uptick in international patent filings for the second straight year; the Federal ...

Dementia often affects memory, thinking, behavior and daily functioning — now, a new case study reveals a novel symptom that ...

Coinbase CEO Brian Armstrong faces a derivative lawsuit alleging misleading disclosures on custody risks, token listings, and AML controls from 2021-2023.